Marshall Wace North America’s Acadia Pharmaceuticals ACAD Stock Holding History

Marshall Wace North America’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,545	Closed	-$246K	–	1401
2021 Q1	$246K	Sell	9,545 -418,902	-98%	-$18.4M	﹤0.01%	1359
2020 Q4	$22.9M	Sell	428,447 -790,742	-65%	-$39.3M	0.1%	222
2020 Q3	$50.3M	Buy	1,219,189 +1,194,767	+4,892%	+$51.6M	0.32%	74
2020 Q2	$1.18M	Buy	+24,422	New	+$1.17M	0.01%	718
2020 Q1	–	Sell	-31,115	Closed	-$1.33M	–	1178
2019 Q4	$1.33M	Buy	+31,115	New	+$1.35M	0.01%	665
2018 Q3	–	Sell	-198,214	Closed	-$3.03M	–	889
2018 Q2	$3.03M	Buy	+198,214	New	+$3.53M	0.02%	651

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Marshall Wace North America's ACAD Position: Q2 2021 in Review

Marshall Wace North America sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 9,545 shares — an estimated $246K sold.

Marshall Wace North America first reported a position in ACAD in Q2 2018 and held it in 6 quarters. The position peaked at $50.3M in Q3 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

Marshall Wace North America reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 9,545 Acadia Pharmaceuticals shares in Q2 2021, an estimated $246K.
Marshall Wace North America first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 6 quarters.
Marshall Wace North America's Acadia Pharmaceuticals position peaked at $50.3M in Q3 2020.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.